Skip to content

Progressive Resistance Training Versus Total Hip Arthroplasty in Patients With Hip Osteoarthritis

Progressive Resistance Training Versus Total Hip Arthroplasty in Patients With End-stage Hip Osteoarthritis (PROHIP): A Multicentre, Parallel-group, Randomised Controlled Superiority Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04070027
Acronym
PROHIP
Enrollment
109
Registered
2019-08-28
Start date
2019-09-02
Completion date
2026-12-01
Last updated
2026-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hip Osteoarthritis

Keywords

Total Hip Arthroplasty, Total Hip Replacement, Exercise, Progressive Resistance Training, Strength Training, Hip Joint

Brief summary

Hip osteoarthritis is associated with joint pain, physical disability, decreased muscle strength and poor health status, and the most common cause for total hip arthroplasty. No studies have investigated the effect of total hip arthroplasty compared to non-surgical treatment in patients with end-stage hip osteoarthritis. This comparison is of upmost importance as it is unknown whether non-surgical treatment may be used as an alternate to surgery. The purpose of this study is to investigate whether total hip arthroplasty followed by standard care is superior to progressive resistance training for improving hip function and pain in patients with end-stage hip osteoarthritis. The hypothesis is that patients treated with total hip arthroplasty will improve more than patients treated with progressive resistance training.

Detailed description

Hip osteoarthritis (OA) is associated with joint pain, dysfunction of activities of daily living (ADL), decreased muscle strength and decline in health-related quality of life status, and the most common cause for total hip arthroplasty (THA). In Denmark, approximately 10.400 primary THA surgeries are performed annually, and the yearly incidence rate of this procedure has increased dramatically from 80 to 180 per 100.000 persons between 1995 and 2016. However, some patients experience long-term pain and may never recover full physical function and muscle strength after surgery. Exercise has been shown to improve physical function and reduce pain in people with hip OA, and is recommended initially as a treatment in international clinical guidelines. Furthermore, a recent randomised controlled trial (RCT) showed clinically relevant improvements in ADL and muscle function after 10-weeks of supervised explosive-type progressive resistance training (PRT) in patients with end-stage hip OA scheduled for THA compared to standard preoperative care. To date, no RCTs have investigated the effect of THA followed by standard postoperative care compared to supervised explosive-type PRT in patients with end-stage hip OA. Therefore, this highlights the need for a high-quality trial as it is unknown whether non-surgical treatment may be used as an alternate to surgery. The aim of this randomised controlled trial is to investigate whether THA followed by standard care is superior to a 12-week supervised explosive-type PRT programme for improving patient-reported hip function and pain 6 months after initiating the intervention, measured using the Oxford Hip Score (OHS), in patients with end-stage hip OA eligible for THA. Exploratory outcome time-points will be assessed at 3, 12, 24 and 60 months after initiating the intervention. The hypothesis is that THA followed by standard care is superior to a 12-week supervised explosive-type PRT programme for improving patient-reported hip function and pain 6 months after initiating the intervention, measured using the OHS, in patients with end-stage hip OA eligible for THA. Observational cohort: Patients fulfilling the eligibility criteria but declining to participate in the RCT will be asked to participate in a prospective observational cohort study using the same primary end-point (6 months), exploratory time-points (3, 12, 24 and 60 months), and patient-reported outcomes, but following usual clinical practice.

Interventions

PROCEDURETotal Hip Arthroplasty

Total hip arthroplasty following standard procedures.

OTHERProgressive Resistance Training

Progressive resistance training based on available evidence on patients with hip osteoarthritis and designed in accordance with the "American College of Sports Medicine" (ACSM) recommendations for progression models in resistance training aiming at inducing muscle hypertrophy and increasing muscle strength and power.

Sponsors

Vejle Hospital
Lead SponsorOTHER
Odense University Hospital
CollaboratorOTHER
Naestved Hospital
CollaboratorOTHER
Aarhus University Hospital
CollaboratorOTHER
The Danish Rheumatism Association
CollaboratorOTHER
Region of Southern Denmark
CollaboratorOTHER
Association of Danish Physiotherapists
CollaboratorOTHER
The Research Council at Naestved-Slagelse-Ringsted Hospitals
CollaboratorUNKNOWN

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Adults aged ≥50 years 2. Clinical history and symptoms consistent with primary hip osteoarthritis (including hip osteoarthritis due to mild hip dysplasia that may be treated with standard components) and radiographic verified hip osteoarthritis defined as joint space narrowing \<2 mm 3. Considered eligible for total hip arthroplasty by an orthopaedic surgeon (i.e. duration of symptoms \>3 months, hip related pain, functional impairment or decreased range of motion (ROM), and attempted treatment with analgesics)

Exclusion criteria

1. Severe walking deficits (dependency of two crutches or walker) 2. Body Mass Index \>35 kg/m2 3. Lower extremity fractures within one-year prior to inclusion 4. Planned other lower extremity surgery within six months 5. Cancer diagnosis and receiving chemo-, immuno- or radiotherapy 6. Neurological diseases (e.g. previous stroke, multiple sclerosis, Parkinson's, Alzheimer's). 7. Other reasons for exclusion (i.e. inadequacy in written and spoken Danish, mentally unable to participate, physically unable to comply with the PRT protocol due to comorbidity (e.g. severe heart disease, previous major lower extremity surgery within six-months) etc.).

Design outcomes

Primary

MeasureTime frameDescription
Change in the Oxford Hip Score (OHS) from baseline to 6 months6 monthsThe OHS is a 12-item patient-reported outcome measure designed to assess hip function and pain within the last four weeks among patients suffering from hip osteoarthritis in one score. The total score ranges from 0 to 48, with higher scores indicating better disease status.

Secondary

MeasureTime frameDescription
Change in the University of California Los Angeles (UCLA) Activity Score6 monthsThe UCLA Activity Score is a single-item patient-reported outcome measure designed to assess physical activity level. The score ranges from 1 to 10, with higher scores indicating greater physical activity level.
Change in the 40 metre Fast Paced Walk Test (40m-FPWT) from baseline to 6 months6 monthsThe 40m-FPWT is a physical function test designed to assess short distance maximum walking speed (meters/second).
Change in the 30 second Chair Stand Test (30s-CST) from baseline to 6 months6 monthsThe 30s-CST is a physical function test designed to assess sit-to-stand function (number of repetitions).
Number of Serious Adverse Events (SAE) from baseline to 6 months6 months.SAE according to the International Conference on Harmonisation-Good Clinical Practice (ICH-GCP) guidelines will be collected from The Danish National Patient Registry and medical record review conducted at the 6 months follow-up. Furthermore, a short patient-reported questionnaire at the 3 and 6 months follow-up will be used to ensure that all SAE are recorded.
Change in the Hip disability and Osteoarthritis Outcome Score (HOOS) pain subscale from baseline to 6 months6 monthsThe HOOS pain subscale is a 10-item patient-reported outcome measure designed to assess hip pain in patients with hip osteoarthritis. The total score ranges from 0 to 100, with higher scores indicating better pain status.
Change in the HOOS symptoms subscale from baseline to 6 months6 monthsThe HOOS pain subscale is a five-item patient-reported outcome measure designed to assess other hip symptoms in patients with hip osteoarthritis. The total score ranges from 0 to 100, with higher scores indicating better symptoms status.
Change in the HOOS activities of daily living (ADL) function subscale from baseline to 6 months6 monthsThe HOOS ADL function subscale is a 17-item patient-reported outcome measure designed to assess ADL function in patients with hip osteoarthritis. The total score ranges from 0 to 100, with higher scores indicating better ADL function status.
Change in the HOOS sports and recreation subscale from baseline to 6 months6 months.The HOOS sports and recreation subscale is a four-item patient-reported outcome measure designed to assess sports and recreation function in patients with hip osteoarthritis. The total score ranges from 0 to 100, with higher scores indicating better sports and recreation status.
Change in the HOOS quality-of-life subscale from baseline to 6 months6 monthsThe HOOS quality-of-life subscale is a four-item patient-reported outcome measure designed to assess hip-related quality-of-life in patients with hip osteoarthritis. The total score ranges from 0 to 100, with higher scores indicating better quality-of-life status.

Countries

Denmark

Contacts

PRINCIPAL_INVESTIGATORThomas Frydendal, PT, MSc

University of Southern Denmark

STUDY_DIRECTORSøren Overgaard, Prof., MD

Odense University Hospital and University of Southern Denmark

STUDY_CHAIRInger Mechlenburg, Prof., DMSc

Aarhus University Hospital and Aarhus University

STUDY_CHAIRKim Gordon Ingwersen, PT, PhD

University of Southern Denmark

STUDY_CHAIRLone Ramer Mikkelsen, PT, PhD

Silkeborg Regional Hospital

STUDY_CHAIRRobin Christensen, Prof., PhD

The Parker Institute and Odense University Hospital

STUDY_CHAIRClaus Varnum, PhD, MD

Vejle Hospital

STUDY_CHAIRHenrik Morville Schrøder, PhD, MD

Naestved Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 22, 2026